Abstract: Waldenstrm's macroglobulinemia (WM)/lymphoplasmictic lymphoma (LPL) is a rare,  incurable Bcell lymphoma. Its clinical course  is characterized by elevated immunoglobulinM (IgM) levels,  lymphoplasmacytic bone marrow  infiltration with cytopenia,  hepatomegaly,  splenomegaly,  and lymphadenopathy.Recently,  great progress has been made to better explain the pathobiology of WM,  which has  identified several clinical and genetic markers that serve prognosticate disease course and  patient outcomes. This article reviews some of the recent advance with  respect to prognostic markers and new treatments that are currently in progress.

Key words: Waldenstrm macroglobulinemia, lymphoplasm, , smallcell, immunoglobulin M